2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Bioinformatics, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Immunology, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

1395 Progression from biochemical to clinically significant breakthrough hemolysis defines distinct disease trajectories in paroxysmal nocturnal hemoglobinuria

Mark David Orland, MD, PhD, Aashray Mandala, BS2, Serhan Unlu, MD3, Luca Guarnera, MD4, Nandini Rajaram Siva, MD5, Carlos Bravo-Perez, MD6, Valeria Visconte, PhD7, Carmelo Gurnari, MD,PhD8, Jaroslaw P. Maciejewski, MD, PhD, FACP9
1 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States, Tor Vergata University, Rome, Italy
5 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States, Hospital Universitario Morales Meseguer, University of Murcia, IMIB-Pascual Parrilla, CIBERER - Instituto de Salud Carlos III, Murcia, Spain
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States, Tor Vergata University, Rome, Italy
9 Cleveland Clinic, Cleveland, Ohio, United States

Background

Complement inhibition has transformed outcomes in paroxysmal nocturnal hemoglobinuria (PNH), yet breakthrough hemolysis (BTH) remains a major cause of morbidity. Breakthrough is hierarchical rather than categorical: every clinically significant episode begins as a biochemical event, but only a subset progresses. The determinants governing transition from biochemical complement escape to clinical consequence remain undefined.

Methods

We retrospectively analyzed an institutional PNH cohort of 423 patients with PNH clones. Among these, 117 patients with longitudinal complement inhibitor exposure and sufficient follow-up for event adjudication contributed 222 discrete treatment periods and 720.9 person-years (PY) of observation. Exposure comprised eculizumab 444.1 PY, ravulizumab 169.1 PY, iptacopan 61.7 PY, and pegcetacoplan 46.0 PY. Each episode was sequentially adjudicated as biochemical (hemoglobin decline ≥1.5 g/dL or LDH ≥1.5× upper limit of normal) and clinically significant. Determinants of occurrence were modeled per person-time. Progression was modeled by binomial regression with each patient contributing one observation, clinical episodes as numerator and biochemical episodes as denominator, making the patient the unit of analysis. Sustained hemolysis, recurrence, thrombosis, and prediction were evaluated separately.

Results

We identified 156 biochemical breakthrough episodes in 55 patients (21.6/100 PY); median time to first BTH was 6.6 years. Of 156 episodes, 89 (57%) progressed to clinical significance and 67 remained biochemical alone. Occurrence and progression had distinct determinants. Biochemical breakthrough was associated with granulocyte clone burden and anemia: granulocyte clone ≥50% doubled the breakthrough rate (23.7 vs 10.8/100 PY; IRR 2.20, P=0.003), lower baseline hemoglobin increased risk (IRR 0.85/g/dL, 95% CI 0.73–0.99; P=0.031), and non-responding treatment periods had higher rates than responding periods (IRR 1.74, P=0.002). In contrast, progression reflected hematopoietic reserve and baseline somatic myeloid mutations. Baseline neutropenia (ANC <1.5 K/µL) was associated with progression in 80% versus 48% of episodes (OR 4.27, 95% CI 1.60–11.40; P=0.004), and a smaller PNH red cell clone was independently associated with progression (OR 0.985 per %, 95% CI 0.973–0.997; P=0.012). Exploratory genomic analysis identified baseline myeloid panel mutation status as a candidate biomarker: carriers progressed in 78% versus 53% of episodes (OR 3.14, 95% CI 1.19–8.29; P=0.021), an association independent of RBC clone size, while the association between ANC and progression was no longer observed in joint models. Hemoglobin predicted occurrence, but not progression (OR 0.85, 95% CI 0.72–1.01; P=0.06).

Among 46 patients with episode detail, 23 (50%) required transfusion and 17 (37%) underwent treatment modification. Recurrent breakthrough occurred in 40 of 117 patients (34%), was not predicted by baseline features (all P≥0.11), and rose only after an initial event (29.9 episodes/100 PY), suggesting an acquired state. Thrombosis represented a distinct disease axis: thrombotic patients had similar BTH burden (IRR 1.07, P=0.72), thrombosis preceded breakthrough in 13 patients versus 3, 16 of 32 never hemolyzed, and 24 of 27 events were venous.

Proximal agents contributed only 15% of observation time and 13 of 156 episodes; in exposure-matched 24-month windows breakthrough was lower than with terminal inhibition (IRR 0.25, P=0.005), limited by follow-up. Baseline clinical variables did not reliably predict breakthrough, recurrence, or thrombosis after internal validation.

Conclusions

Breakthrough hemolysis during complement inhibition is a two-step process. Granulocyte clone burden and anemia determine susceptibility to biochemical complement escape, whereas progression to clinically significant breakthrough appears to reflect hematopoietic reserve and baseline somatic myeloid mutations rather than the severity of hemolysis itself. Exploratory analyses nominate baseline myeloid panel mutation status as a candidate genomic biomarker of progression warranting prospective validation. Thrombosis is largely uncoupled from on-treatment hemolysis and represents a parallel disease axis. These findings support interpreting BTH through progression risk rather than biochemical severity alone.

Mark David Orland, MD, PhD: No relevant conflicts of interest to declare.